Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
Chronic Rhinosinusitis (Diagnosis)Nasal Polyps
Interventions
BIOLOGICAL

CM310

300 mg every two weeks

BIOLOGICAL

Placebo

300 mg every two weeks

Trial Locations (19)

Unknown

Beijing Chaoyang Hospital, CMU, Beijing

Beijing Hospital, Beijing

Beijing Renmin Hospital, Beijing

Beijing Tongren Hospital, CMU, Beijing

First Affiliated Hospital of Chongqing Medical University, Chongqing

Jingzhou Central Hospital, Jingzhou

Renmin Hospital of Wuhan University, Wuhan

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

Third Xiangya Hospital of Central South University, Changsha

The First Affiliated Hospital of Nanchang University, Nanchang

Affiliated Hospital of Qingdao University, Qingdao

Yantai Yuhuangding Hospital, Yantai

Shandong Second Provincial General Hospital (Shandong ENT hospital), Jinan

Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai

Tongji Hospital of Tongji University, Shanghai

Second Hospital of Shanxi Medical University, Taiyuan

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu

West China Hospital of Sichuan University, Chengdu

Zhejiang Provincial People's Hospital, Hangzhou

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT04805398 - Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1) | Biotech Hunter | Biotech Hunter